Arthneeti
Latest: Dr Reddys Laboratories Ltd Q2 FY27 (Jul–Sep 2026) results →This page is Q1 FY27 (Apr–Jun 2026).All Q1 FY27 results →
DR

Dr Reddys Laboratories Ltd

Q1 FY27Pharmaceuticals & Biotechnology

Dr Reddys Laboratories Q1 FY27 earnings call: Revenue & Margins

Q1 FY27 earnings call: what management said on revenue, margins and capex.

Price₹1,233
Market cap₹1.0L Cr
P/E31.9
Updated16 Oct 2026
Read3 min read

What the Q1 FY27 call signalled

1 of 3 strong

RevenueModerate growth
MarginMargins steady
CapexCapex planned

The short version

Dr. Despite the current supply setback with semaglutide, Dr.

From Dr Reddys Laboratories Ltd's Q1 FY27 earnings-call transcript · updated 16 Oct 2026.

Revenue & Sales Performance

Moderate growth
  • Dr. Reddy's expects to supply 6 to 7 million semaglutide pens between Q3 and Q4 of FY27, despite a delay caused by API scale-up validation issues.
  • The original annual target was 12 million pens in the first year of launch; the delay means this target may be missed.
  • Demand remains robust, outstripping supply, with no anticipated decrease, despite competitive pressure.
  • Plans for in-house captive manufacturing remain on track, albeit with a delay of a few months beyond prior timelines.
  • Long-term partnership with OneSource continues, supporting a reliable supply chain for many years.

2 more points from Dr Reddys Laboratories Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Dr Reddys Laboratories Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Capex planned
  • Dr. Reddy's is progressing with plans for captive manufacturing of semaglutide to supplement supply from OneSource.
  • There is no change to these plans despite the current impurity-related manufacturing delays.
  • The in-house facility will require API validation before full-scale production, causing a potential delay of a few months beyond original timelines.

2 more points from Dr Reddys Laboratories Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
1KRM Ayurveda
Rev 1Mar 1
2Accretion Pha.
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Dr Reddys Laboratories Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

  • Dr. Reddy's is currently facing a temporary supply halt for semaglutide injection due to an impurity issue detected in scale-up API batches.
  • The company expects to resolve the issue and resume commercial supply by late October to early November 2026.
  • They anticipate supplying approximately 6 to 7 million semaglutide pens between Q3 and Q4 of fiscal year 2027.
  • This supply estimate reflects a shortened selling window compared to the original full-year target of 12 million pens.
  • The firm is committed to a long-term partnership with OneSource for supply alongside their own manufacturing facilities.

2 more points from Dr Reddys Laboratories Ltd's call on order book

Create a free account to keep reading this call

Dr Reddys Laboratories Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹8.7K Cr, net profit ₹913 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Dr Reddy's Labs's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • KRM Ayurveda (Q1 FY27)

    Total income for Q1 FY27: ₹3,286.55 Lakhs, +32.4% YoY . Key investor presentation takeaways from KRM Ayurveda Ltd's Q1 FY27 investor presentation — and how it r

  • Balaxi Pharma (Q1 FY27)

    Q1 FY27 Revenue: ₹80.68 crore, up 14.1% YoY from ₹70.74 crore in Q1 FY26 (Page 20). Key investor presentation takeaways from Balaxi Pharma's Q1 FY27 investor pr

  • Sanjiv.Parant. (Q1 FY27)

    Q1 FY27 consolidated revenue from operations: ₹238.39 Mn, up 33.8% YoY from ₹178.92 Mn in Q1 FY26 (Page 25). Key investor presentation takeaways from Sanjivani

  • Natural Capsules (Q1 FY27)

    Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharma.

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Dr Reddys Laboratories Ltd and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Dr Reddys Laboratories Ltd Q1 FY27 results?

Dr. Despite the current supply setback with semaglutide, Dr.

What is Dr Reddys Laboratories Ltd share price analysis?

Dr Reddys Laboratories Ltd currently shows a below-average growth signal. The stock trades at a P/E of 31.9 with a market cap of ₹102,899 Cr. Investors should review the full earnings analysis for detailed insights.

Is Dr Reddys Laboratories Ltd planning capital expenditure?

Dr.

Keep Dr Reddys Laboratories Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.